N
Nabriva Therapeutics
Clinical stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections
About Nabriva Therapeutics
Nabriva Therapeutics is a commercial-stage biopharmaceutical company focused on developing innovative treatments for serious infectious diseases. The company specializes in creating new anti-infective agents, which are medications designed to combat infections caused by bacteria and other pathogens. Nabriva's primary goal is to address the growing issue of antibiotic resistance, which is when bacteria evolve to resist the effects of existing antibiotics, making infections harder to treat.
Read full description
Nabriva operates in the healthcare and pharmaceutical market, targeting hospitals, healthcare providers, and patients who need advanced treatments for severe infections. Their clients include medical professionals who prescribe these treatments and patients who benefit from them.
The company's business model revolves around research and development (R&D) of new drugs, followed by the commercialization of these drugs once they receive regulatory approval. Nabriva invests heavily in R&D to discover and develop new antibiotic candidates. Once a drug is approved, they generate revenue through sales to healthcare providers and institutions.
Nabriva makes money by selling its approved drugs to hospitals and clinics, which then administer these treatments to patients. Additionally, the company may enter into partnerships or licensing agreements with other pharmaceutical companies to expand the reach of their products and share the financial burden of drug development.
In summary, Nabriva Therapeutics is dedicated to creating new solutions for serious infections, addressing a critical need in the healthcare industry. They focus on developing and commercializing new antibiotics to combat antibiotic-resistant bacteria, serving healthcare providers and patients in need of advanced treatments.
At a glance
- Founded
- 2001
- Headquarters
- Dublin, Ireland
- Listing
- IPO 2015
- Sector
- Biotech & Life Sciences
Latest news
Press, funding announcements and product moves mentioning Nabriva Therapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Nomura
HBM Partners
Wellcome Trust
Novartis Venture Fund
Arax Capital Partners
OrbiMed
Phase4 Partners
Vivo Capital
EcoR1 Capital
Series B and later2 investors entered at this stage
Hercules Capital
Armentum Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nabriva Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nabriva Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.